Chronic Kidney Disease Clinical Trial
Official title:
A Phase 1, Single and Multiple Dosing Study to Evaluate Pharmacokinetics and Pharmacodynamics of ASP3325 in Patients With Chronic Kidney Disease and Hyperphosphatemia Undergoing Hemodialysis
Verified date | October 2018 |
Source | Astellas Pharma Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study is to assess PK, safety and tolerability of a single oral dose of ASP3325 and to assess PD, PK and safety of repeated oral doses of ASP3325 administered t.i.d. before or just after each meal
Status | Completed |
Enrollment | 24 |
Est. completion date | November 4, 2014 |
Est. primary completion date | November 4, 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 74 Years |
Eligibility |
Inclusion Criteria: - Subject who has received maintenance hemodialysis 3 times a week for at least 12 weeks (84 days) prior to the scheduled first day of the washout period. - Subject who can receive morning dialysis from the start of the washout period to the end of follow-up period. (Part 2) - Subject with pre-dialysis serum Pi level between =6.0 and <10.0 mg/dL and be confirmed increase in serum Pi of =1.5 mg/dL after the maximum dialysis interval at the washout period week 1 or 2. (Part 2) - Subject who did not change the type or dose of any phosphate binder(s), any nutritional supplements or any other drugs with phosphorus reducing action for at least 4 weeks (28 days) prior to the scheduled first day of the washout period. - Subject who did not receive calcimimetics (e.g., cinacalcet HCl) for at least 12 weeks (84 days) prior to the scheduled first day of the washout period. - Subject taking native or active vitamin D (including vitamin D analogues), calcitonin agents or PTH agents must be on stable dose for at least 4 weeks (28 days) prior to the scheduled first day of the washout period. Exclusion Criteria: - Subject who has a history of severe gastrointestinal disorder, major gastrointestinal surgery, malabsorption considered influential on the absorption of the drug and nutrition in the gastrointestinal tract. - Subject who has a history of parathyroid intervention (e.g., parathyroidectomy [PTx], percutaneous ethanol injection therapy [PEIT]). - Subject whose dry weight loss >5% within 12 weeks (84 days) prior to the scheduled start day of the washout period. - Confirmed serum intact PTH >1000 pg/mL at the start of the washout period (only applicable for Part 2). - Subject whose last 3 measurement values at the separate day of pre-dialysis systolic/diastolic blood pressure before the scheduled start day of the washout period or during the washout period are all 180 mmHg or higher and 120 mmHg or higher. - Subject who has severe congestive heart failure (i.e., NYHA cardiac function classification Class III or severer). - Subject who experienced a myocardial infarction or major surgery excluding vascular access surgery within 12 weeks (84 days) prior to the informed consent signing. - Subject who has any of liver function tests (ALT, AST, T-Bil) out of range as indicated below at the screening (Part 1) or during the washout period, or patients with a complication of serious hepatic disease (e.g., acute and active chronic hepatitis, liver cirrhosis). AST: >2×ULN, ALT: >2×ULN, T-Bil: >1.25×ULN - Subject with history or complication of malignant tumor (considered eligible if recurrence has not been observed for at least 5 years). - Subject with history of serious drug hypersensitivity, such as anaphylactic shock. |
Country | Name | City | State |
---|---|---|---|
Japan | Site: 4 | Aichi | |
Japan | Site: 5 | Aichi | |
Japan | Site: 1 | Ibaraki | |
Japan | Site: 2 | Ibaraki | |
Japan | Site: 3 | Shizuoka |
Lead Sponsor | Collaborator |
---|---|
Astellas Pharma Inc |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety assessed by adverse events: Part 1 | Up to Day 7 | ||
Primary | Safety assessed by adverse events: Part 2 | Up to Day 22 | ||
Primary | Safety assessed by vital signs: Part 1 | Vital signs include body temperature, blood pressure and pulse rate) | Up to Day 7 | |
Primary | Safety assessed by vital signs: Part 2 | Vital signs include body temperature, blood pressure and pulse rate) | Up to Day 22 | |
Primary | Safety assessed by clinical laboratory test: Part 1 | Clinical laboratory tests include hematology and biochemistry | Up to Day 7 | |
Primary | Safety assessed by clinical laboratory test: Part 2 | Clinical laboratory tests include hematology and biochemistry | Up to Day 22 | |
Primary | Safety assessed by 12-Lead ECG: Part 1 | ECG: electrocardiogram | Up to Day 7 | |
Primary | Safety assessed by 12-Lead ECG: Part 2 | ECG: electrocardiogram | Up to Day 22 | |
Secondary | Cmax of unchanged ASP3325 | Cmax:maximum plasma concentration | Part 1 Before administration, Day 1, 2, 4, 5 and 7 | |
Secondary | tmax of unchanged ASP3325 | tmax = time to reach maximum plasma concentration | Part 1 Before administration, Day 1, 2, 4, 5 and 7 | |
Secondary | AUClast of ASP3325 | AUClast: Area under the Curve of plasma concentration during observation period in each observational day | Part 1 Before administration, Day 1, 2, 4, 5 and 7 | |
Secondary | AUCinf of ASP3325 | AUCinf: Area under the Curve of plasma concentration | Part 1 Before administration, Day 1, 2, 4, 5 and 7 | |
Secondary | t1/2 of ASP3325 | t1/2 = apparent terminal elimination half-life | Part 1 Before administration, Day 1, 2, 4, 5 and 7 | |
Secondary | Vz/F of ASP3325 | Vz/F = apparent volume of distribution | Part 1 Before administration, Day 1, 2, 4, 5 and 7 | |
Secondary | CL/F of ASP3325 | CL/F = oral clearance | Part 1 Before administration, Day 1, 2, 4, 5 and 7 | |
Secondary | Ctrough of ASP3325 | Ctrough = observed trough concentration | Part 2 Before administration, Day 3, 5, 8, 10, 12, 15 and 22 | |
Secondary | Serum Pi of ASP3325 | Serum Pi: serum phosphate concentration before dialysis | Part 2 Day -21, -14, and -7 in washout period, Day 1, 8, 15 and 22 | |
Secondary | Serum Calcium (adjusted for albumin) | Corrected value of Calcium (Ca) (mg/dL) = Observed value of Ca (mg/dL) + [4-albumin (g/dL) | Part 2 Day -21, -14, and -7 in washout period, Day 1, 8, 15 and 22 | |
Secondary | Serum concentration of intact PTH before dialysis | PTH = parathyroid hormone | Part 2 Day -21 in washout period, Day 1, 8, 15 and 22 | |
Secondary | Serum concentration of FGF23 | FGF23 = fibroblast growth factor 23 | Part 2 Day -21 in washout period, Day 1, 8, 15 and 22 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |